Longitudinal characterisation of cachexia in patients undergoing surgical resection for cancer.
Journal
Current opinion in supportive and palliative care
ISSN: 1751-4266
Titre abrégé: Curr Opin Support Palliat Care
Pays: United States
ID NLM: 101297402
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
medline:
31
7
2023
pubmed:
30
6
2023
entrez:
30
6
2023
Statut:
ppublish
Résumé
The complexity of the cancer cachexia phenotype has undoubtedly hindered researchers' understanding of this devastating syndrome. The presence and magnitude of host-tumour interactions are rarely considered during clinical decision-making within the current staging paradigm. Furthermore, treatment options for those patients who are identified as suffering from cancer cachexia remain extremely limited. Previous attempts to characterise cachexia have largely focussed on individual surrogate disease markers, often studied across a limited timeframe. While the adverse prognostic value of clinical and biochemical features is evident, the relationships between these are less clear. Investigation of patients with earlier-stage disease could allow researchers to identify markers of cachexia that precede the refractory stage of the wasting process. Appreciation of the cachectic phenotype within 'curative' populations may aid our understanding of the syndrome's genesis and provide potential routes for prevention, rather than treatment. Holistic, longitudinal characterisation of cancer cachexia, across all at-risk and affected populations, is of vital importance for future research in the field. This paper presents the protocol for an observational study aiming to create a robust and holistic characterisation of surgical patients with, or at risk of, cancer cachexia.
Identifiants
pubmed: 37389614
doi: 10.1097/SPC.0000000000000660
pii: 01263393-202309000-00009
doi:
Substances chimiques
Biomarkers
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
172-176Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
von Haehling S, Anker SD. Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014. J Cachexia Sarcopenia Muscle 2014; 5:261–263.
Baracos VE, Martin L, Korc M, et al. Cancer-associated cachexia. Nat Rev Dis Primer 2018; 4:17105.
Kays JK, Shahda S, Stanley M, et al. Three cachexia phenotypes and the impact of fat-only loss on survival in FOLFIRINOX therapy for pancreatic cancer: distinct cachexia phenotypes and survival in PDAC. J Cachexia Sarcopenia Muscle 2018; 9:673–684.
Fearon KCH. Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur J Cancer 2008; 44:1124–1132.
Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011; 12:489–495.
Fearon K, Argiles J, Baracos V, et al. Request for regulatory guidance for cancer cachexia intervention trials: editorial. J Cachexia Sarcopenia Muscle 2015; 6:272–274.
Ramage MI, Skipworth RJE. The relationship between muscle mass and function in cancer cachexia: smoke and mirrors ? Curr Opin Support Palliat Care 2018; 12:439–444.
Temel JS, Abernethy AP, Currow DC, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol 2016; 17:519–531.
Ramage MI, Johns N, Deans CDA, et al. The relationship between muscle protein content and CT-derived muscle radio-density in patients with upper GI cancer. Clin Nutr 2018; 37:752–754.
McGovern J, Dolan RD, Skipworth RJ, et al. Cancer cachexia: a nutritional or a systemic inflammatory syndrome? Br J Cancer 2022; 127:379–382.
Dolan RD, Lim J, McSorley ST, et al. The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: systematic review and meta-analysis. Sci Rep 2017; 7:16717.
Dolan RD, McSorley ST, Horgan PG, et al. The role of the systemic inflammatory response in predicting outcomes in patients with advanced inoperable cancer: systematic review and meta -analysis. Crit Rev Oncol Hematol 2017; 116:134–146.
Patton R, Paval DR, McDonald JJ, et al. Relationship between cytokines and symptoms in people with incurable cancer: a systematic review. Crit Rev Oncol Hematol 2021; 159:103222.
Patton R, Cook J, Haraldsdottir E, et al. REVOLUTION (Routine EValuatiOn of people LivIng with caNcer) – protocol for a prospective characterisation study of patients with incurable cancer. PLoS One 2021; 16:e0261175.
Brierley JD. TNM Classification of Malignant Tumours, 8th ed. John Wiley & Sons; 2017.
Ma D, Chow V, Popuri K, et al. Comprehensive validation of automated whole body skeletal muscle, adipose tissue, and bone segmentation from 3D CT images for body composition analysis: towards extended body composition. arXiv 2021. http://arxiv.org/abs/2106.00652
Mourtzakis M, Prado CMM, Lieffers JR, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 2008; 33:997–1006.
Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 1984; 2:187–193.
Parmar KL, Pearce L, Farrell I, et al. Influence of frailty in older patients undergoing emergency laparotomy: a UK-based observational study. BMJ Open 2017; 7:1–5.
Podsiadlo D, Richardson S. The Timed “Up & Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 1991; 39:142–148.
Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019; 48:16–31.
Bergland A, Jørgensen L, Emaus N, et al. Mobility as a predictor of all-cause mortality in older men and women: 11.8 year follow-up in the Tromsø study. BMC Health Serv Res 2017; 17:22.
Ward WH, Meeker CR, Handorf E, et al. Feasibility of fitness tracker usage to assess activity level and toxicities in patients with colorectal cancer. JCO Clin Cancer Inform 2021; 5:125–133.
McGovern J, Dolan RD, Simmons CPL, et al. Lactate dehydrogenase: relationship with the diagnostic GLIM criterion for cachexia in patients with advanced cancer. Br J Cancer 2023; 128:760–765.
Husi H, Fernandes M, Skipworth R, et al. Identification of diagnostic upper gastrointestinal cancer tissue type-specific urinary biomarkers. Biomed Rep 2019; 10:165–174.
Altobelli E, Angeletti PM, Latella G. Role of urinary biomarkers in the diagnosis of adenoma and colorectal cancer: a systematic review and meta-analysis. J Cancer 2016; 7:1984–2004.
Husi H, Donald AM, Skipworth RJE, et al. Urinary diagnostic proteomic markers for dynapenia in cancer patients. Biomed Rep 2018; 8:547–556.
Stephens NA, Skipworth RJE, Gallagher IJ, et al. Evaluating potential biomarkers of cachexia and survival in skeletal muscle of upper gastrointestinal cancer patients: evaluating potential biomarkers of cachexia and survival. J Cachexia Sarcopenia Muscle 2015; 6:53–61.
Miller J, Dreczkowski G, Ramage MI, et al. Adipose depot gene expression and intelectin‐1 in the metabolic response to cancer and cachexia. J Cachexia Sarcopenia Muscle 2020; 11:1141–1153.